Your browser doesn't support javascript.
loading
Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignancies.
Ikeda, Daisuke; Terao, Toshiki; Fukumoto, Ami; Uesugi, Yuka; Tabata, Rikako; Kuzume, Ayumi; Tsushima, Takafumi; Miura, Daisuke; Narita, Kentaro; Takeuchi, Masami; Yamashita, Takeshi; Takamatsu, Hiroyuki; Matsue, Kosei.
Affiliation
  • Ikeda D; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Terao T; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Fukumoto A; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Uesugi Y; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Tabata R; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Kuzume A; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Tsushima T; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Miura D; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Narita K; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Takeuchi M; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
  • Yamashita T; Division of Internal Medicine, Keiju Kanazawa Hospital, Ishikawa, Japan.
  • Takamatsu H; Faculty of Medicine, Department of Haematology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
  • Matsue K; Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
Br J Haematol ; 200(5): 568-572, 2023 03.
Article in En | MEDLINE | ID: mdl-36345272
ABSTRACT
Antibody titres in 462 patients with haematological malignancies after the second (D2) and third (D3) SARS-CoV-2 vaccine were compared with those of healthy controls (HCs). Significant decay of antibody titre was observed pre D3, but titre surged post D3. The number of seronegative patients decreased from 79 (17.1%) to 44 (9.5%) from post D2 to post D3, and patients with adequate antibody titre increased from 204 (44.2%) to 358 (77.5%). Of the patients who received B-cell-targeted therapy, 80% were seronegative and 71% remained seronegative after D3. CD19+, CD4+, CD8+ cell counts, and immunoglobulin G (IgG) levels were identified as independent predictors for adequate serologic response.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Limits: Humans Language: En Journal: Br J Haematol Year: 2023 Document type: Article Affiliation country: Japón
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Limits: Humans Language: En Journal: Br J Haematol Year: 2023 Document type: Article Affiliation country: Japón